Andere Sprachen Taysha Gene Therapies, Inc.

Aktien

A2QCJL

US8776191061

TSHA

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 25.04.2024			% 5 Tage	% 1. Jan.
2.3 ^USD	-2.13%		-4.56%	+29.94%

09.04.	TAYSHA GENE THERAPIES, INC. : Piper Sandler bleibt bei seiner Kaufempfehlung	ZM
21.03.	TAYSHA GENE THERAPIES, INC. : Chardan Research bekräftigt seine Kaufempfehlung	ZM

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	05.04.
Wall Street Set to Open Flat as Investors Look Toward Fed Decision; Oil Prices Drop Sharply	20.03.
US Futures Flat in Wednesday's Premarket as Investors Await Fed's Interest Rate Decision	20.03.
Top Premarket Gainers	20.03.
Taysha Gene Therapies Surges 26% Premarket After Full-Year 2023 Results Show Narrowing Net Loss, Surging Revenue	20.03.
North American Morning Briefing : Markets on Hold as Fed Decision Nears	20.03.
Taysha Gene Therapies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	19.03.
Taysha Gene Therapies Reports Full Year 2023 Financial Results and Provides Corporate and Clinical Updates	19.03.
Taysha Gene Therapies to Release Full-Year 2023 Financial Results, Provide Corporate and Clinical Updates and Host Conference Call on March 19	14.03.
Taysha Gene Therapies : March 2024 Corporate Presentation	08.03.
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	01.03.
Taysha Gene Therapies Announces Updates to TSHA-102 Clinical Program in Rett Syndrome	29.02.
Taysha Gene Therapies Provides Update on Deprioritized Pipeline Programs	15.02.
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	02.02.
Taysha Gene Therapies Announces Poster Presentation on TSHA-102 in Rett Syndrome at Upcoming British Paediatric Neurology Association 2024 Annual Conference	22.01.
Taysha Gene Therapies Announces First Pediatric Patient Dosed with TSHA-102 in REVEAL Phase 1/2 Pediatric Trial in Rett Syndrome	10.01.
Taysha Gene Therapies, Inc. Announces First Pediatric Patient Dosed with TSHA-102 in REVEAL Phase 1/2 Pediatric Trial in Rett Syndrome	10.01.
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	05.01.
Trinity Capital Inc. Provides $40 Million Term Loan to Taysha Gene Therapies	19.12.
Taysha Gene Therapies, Inc.(NasdaqGS:TSHA) added to NASDAQ Biotechnology Index	18.12.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Taysha Gene Therapies, Inc.

Aktien

A2QCJL

US8776191061

TSHA

Andere Sprachen

Filter